Istesso Announces FDA Fast Track and Orphan Drug Designation for MBS2320

December 5, 2022 -- Istesso Limited, the immunometabolism drug discovery and development company, today announces that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for Istesso’s investigational metabolic...
Source: Drugs.com - Clinical Trials - Category: Pharmaceuticals Source Type: clinical trials